These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 21074069)

  • 1. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 6. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
    Callahan MK; Wolchok JD; Allison JP
    Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
    Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
    Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
    Eggermont AM; Testori A; Maio M; Robert C
    Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].
    Ladányi A; Balatoni T
    Magy Onkol; 2013 Jun; 57(2):100-7. PubMed ID: 23795355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
    Bakacs T; Mehrishi JN; Szabó M; Moss RW
    Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.